Brief: Cereno Scientific - New Preclinical Data Show Dose Dependent Positive Impact On Reversal Of Pulmonary Vascular Remodeling By Novel HDACi CS014
25/09/2024 07:10
Sept 25 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* NEW PRECLINICAL DATA DEMONSTRATE DOSE DEPENDENT POSITIVE
IMPACT
ON REVERSAL OF PULMONARY VASCULAR REMODELING BY CERENO
SCIENTIFIC'S NOVEL HDACI CS014
Source text for Eikon: ID:nWkrbDX6Kh
Further company coverage: CRNOSb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global